1. Home
  2. Labeler Index
  3. Bryant Ranch Prepack
  4. 71335-2337
  5. Product Images: Levetiracetam

Product Images Levetiracetam

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 8 images provide visual information about the product associated with Levetiracetam NDC 71335-2337 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Label - lbl713352337

Label - lbl713352337

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2

Figure 2 shows the Responder Rate in Study 2 during Period A, indicating a 250% reduction from the baseline. The percentages range from 0% to 40%, with the highest percentage being 35.2%. The graph also includes the percentages of patients at different levels, from 2% to 15%. The study compares the effectiveness of a placebo (N=111) with two different doses of Levetiracetam, 1000 mg/day (N=106) and 2000 mg/day (N=105). The asterisk (*) indicates that the difference in response rate between the highest dose of Levetiracetam and the placebo is statistically significant.*

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3

This text provides information on the responder rate in Study 3, indicating the percentage of participants who experienced a greater than 50% reduction from baseline. The percentages shown range from 45% to 5%, with specific values given for each group. The study involved a placebo group (N=104) and a group taking levetiracetam at a dosage of 3000 mg/day (N=180). The text also mentions that the levetiracetam group had statistically significant results compared to the placebo group.*

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4

Figure 4 shows the responder rate in Study 4, indicating a 50% reduction from the baseline. The percentages range from 44.6% to 45% for the treatment group. The placebo group, comprising 97 participants, had a responder rate of 19.6%. The drug Levetiracetam, which had 101 participants, showed statistically significant improvement compared to the placebo group.*

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5

Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6

Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6

This text describes the Responder Rate in Study 7 for patients with PGTC seizures. The graph shows the reduction in seizure frequency per week, with a 250% reduction from the baseline. The percentages indicate the responder rate, with the placebo group showing a rate of 72.2% and the levetiracetam group showing a rate of 45.2%. The text also mentions that 9% of patients experienced a statistically significant reduction in seizures compared to the placebo group.*

Chemical Structure - levetiracetam str

Chemical Structure - levetiracetam str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.